Elanco CEO Jeff Simmons on Animal Health Growth, New Products, and Market Resilience

Elanco's Strong Financial Performance

• 📈 Elanco Animal Health shares surged, hitting a 52-week high, following better-than-expected second-quarter results.
• 🎯 The company boosted its full-year adjusted earnings per share and revenue guidance, demonstrating strong performance.
• 🚀 Elanco has achieved eight consecutive quarters of accelerating growth, with a recent peak of 8% on an adjusted basis.

Resilient Animal Health Industry Trends

• 💡 The animal health industry is highlighted as one of the most resilient sectors, driven by trends in both pet ownership and protein consumption.
• 🐶 Global pet ownership is increasing, with owners showing a greater willingness to spend on their pets, even as human birth rates decline.
• 🥩 On the protein side, converging trends in new protein diets and farmer needs are creating a resilient market for animal health products.

Driving Growth Through Innovation

• 🔑 Innovation is the primary driver of growth for Elanco, with a focus on developing valuable products for farmers and veterinarians.
• 🐕 Credelio Quattro, a new parasiticides product for fleas, ticks, and heartworm, has captured 14% market share in a rapidly growing segment.
• 🐾 Zenrelia, a product for atopic dermatitis in dogs, is showing high efficacy, with over 50% of users moving it to first-line treatment.
• 🐄 Products for the cattle business are also contributing to growth by improving productivity and addressing environmental impacts.

Navigating the Regulatory and Supply Chain Environment

• ⚠️ Elanco is actively navigating the tariff environment, having implemented interventions and quantified potential impacts within its guidance.
• 🇺🇸 The company emphasizes that its manufacturing is primarily based in Europe and the US, with a minimal percentage of active ingredients sourced from China.
• 🚫 Elanco believes its business model, focused on cash-based transactions without a payer or insurance system, places it out of scope for broader pharmaceutical tariff discussions.

The Future of Animal Health Innovation

• 🎯 Innovation in pet pharmaceuticals is driven by identifying market needs and adding demonstrable value.
• 🔬 Elanco focuses on developing best-in-class or first-in-class products with differentiated value, pricing them competitively from day one.
• 🌟 The company is well-positioned for continued value creation throughout the decade, with a strong outlook beyond 2025.